Dr. Mohindru is a skilled biotech executive with several years of biopharmaceutical industry leadership, coupled with experience on Wall Street. Dr. Mohindru currently serves as the chief executive officer at Novasenta, a biotech company focused on discovering novel targets for the treatment of cancer. Dr. Mohindru has served in numerous company leadership positions, including chief executive officer at CereXis, chief financial officer and chief strategy officer at Cara Therapeutics (Nasdaq: CARA) and chief strategy officer at Curis, Inc. (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent many years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. She also co-founded a privately- held biotechnology company and was a healthcare industry consultant. Currently, she is a member of the board of directors of SAB Biotherapeutics, a clinical-stage biopharmaceutical company advancing a new class of immunotherapies. Dr. Mohindru received her Ph.D. in neurosciences from Northwestern University, her master’s degree in biotechnology, and her B.S. in human biology with honors from the All India Institute of Medical Sciences, New Delhi, India.